01/06/2026
📣 Big Update in Weight Loss Care – New for 2026
Oral semaglutide has officially entered a new chapter.
In December 2025, the FDA approved Wegovy® tablets (oral semaglutide) for chronic weight management in adults with obesity or overweight with at least one weight-related condition. This approval also includes cardiovascular risk-reduction benefits for certain adults with established heart disease.
What does this mean for patients considering non-injectable options?
Who may qualify?
And how does oral semaglutide compare to injectable GLP-1 medications?
We’ve broken it all down in our updated blog post so you can make informed, confident decisions about your health.
👉 Read the full update on our blog: https://www.poterehealthmd.com/post/wegovy-tablets-oral-semaglutide-25mg-fda-approval
What Is Oral Semaglutide and What Changed in 2025?
As always, our care remains physician-led, evidence-based, and personalized.
—
Potere Health MD
Affordable, ethical medical weight loss 💙